rs30021 — SNX24 VEGFA Vascular Growth Co-variant

Intronic variant in SNX24 (sorting nexin 24) with roles in vascular endothelial inflammation and platelet alpha-granule biogenesis, including VWF and P-selectin trafficking; G allele is minor and may reduce SNX24 expression efficiency in endothelial and megakaryocyte lineages

See your personal result for SNX24

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SNX24 and Vascular Homeostasis — The Sorting Nexin That Guards Your Vessel Walls

Inside every vascular endothelial cell and platelet-producing megakaryocyte, a molecular sorting system routes proteins to exactly where they need to go. SNX24 — sorting nexin 2411 SNX24 — sorting nexin 24
a member of the PX-domain sorting nexin family; binds phosphoinositide lipids on endosomal membranes and guides cargo vesicles through the intracellular trafficking network — is one component of this system, specifically required for building platelet alpha-granules and regulating endothelial cytokine output. The rs30021 variant lies deep within the SNX24 gene (c.249+4040G>A), in a non-coding intron region that may influence how much SNX24 is produced in vascular tissues.

While rs30021 itself has not been the direct subject of a published clinical trial, it sits in a biologically rich locus. SNX24's documented roles — controlling von Willebrand factor (VWF) release from platelets and modulating the endothelial inflammatory response — are directly relevant to cardiovascular and venous disease. The G allele of rs30021 is uncommon globally (~23% allele frequency), with marked variation across ancestries: European populations carry it at ~31%, East Asian populations at just ~1%.

The Mechanism

SNX24 acts in the alpha-granule maturation pathway22 alpha-granule maturation pathway
alpha-granules are the most abundant organelle in platelets, storing key hemostatic proteins including VWF, P-selectin, fibrinogen, and platelet factor 4 of megakaryocytes — the bone marrow precursor cells that produce platelets. When SNX24 is knocked out experimentally, megakaryocytes accumulate empty membrane vesicles, fail to form mature multivesicular bodies, and produce platelets that are severely depleted in alpha-granule cargo including VWF and CD62P (P-selectin). These proteins are critical for the initial steps of hemostasis and thrombus formation at sites of vascular injury.

In endothelial cells, SNX24 plays a second, independent role: modulating the inflammatory cytokine response to bacterial lipopolysaccharide. When SNX24 expression is suppressed, endothelial cells produce significantly less IL-1β, IL-6, and IL-8 in response to inflammatory signals. This positions SNX24 as a regulator of endothelial activation — the cellular process that initiates leukocyte recruitment, promotes coagulation, and drives the vascular inflammatory response underlying atherosclerosis and venous wall remodeling.

The rs30021 intronic variant (c.249+4040G>A) does not change the SNX24 protein sequence directly. Deeply intronic variants can influence gene expression through effects on splicing enhancers, intronic regulatory elements, or chromatin accessibility. Whether rs30021 affects SNX24 expression in endothelial or megakaryocyte lineages has not been characterized experimentally.

The Evidence

The direct evidence for rs30021 is limited: no published GWAS hit, no ClinVar entry, and no primary study investigating its phenotypic consequence. It appears in the related-variant set of the VEGFA/5q region varicose vein GWAS context, identified in Ahmed et al. 202233 Ahmed et al. 2022
two-stage analysis across 810,000 participants identifying 49 genome-wide significant varicose vein loci.

The biological evidence for SNX24's vascular role is stronger. Lacey et al. 202244 Lacey et al. 2022
CRISPR-Cas9 knockout in iPSC-derived megakaryocytes; n=3 cell lines per condition demonstrated that SNX24 loss eliminates alpha-granule maturation, with direct measurement of VWF reduction — a key coagulation factor also implicated in venous thromboembolism. A separate genetic study Lin et al. 201355 Lin et al. 2013
262 Kawasaki disease patients, 76 with coronary artery aneurysm showed that SNX24 variant rs28891 (a different coding variant in the same gene) associates with coronary artery aneurysm severity, and that endothelial cells with reduced SNX24 expression produce less IL-1β, IL-6, and IL-8 — directly connecting SNX24 function to vascular inflammation.

Given the indirect nature of evidence for rs30021 specifically, this SNP is rated emerging. The classification may be upgraded if eQTL studies confirm that rs30021-G reduces SNX24 expression in vascular or platelet precursor tissues.

Practical Actions

For G allele carriers, the theoretical concern is reduced SNX24 expression in two cell types: megakaryocytes (platelets) and endothelial cells. Reduced SNX24 in megakaryocytes could impair alpha-granule loading, affecting VWF release and platelet adhesion capacity at vascular injury sites. Reduced SNX24 in endothelium could reduce inflammatory cytokine output — a potentially protective effect that makes the directionality of this variant complex.

Monitoring VWF levels (including VWF antigen and activity) can capture downstream effects of platelet alpha-granule dysfunction. VWF Ag below 50% is defined as von Willebrand disease type 1, though this is generally driven by VWF gene variants; moderately low VWF activity (50–100%) influences both bleeding tendency and, paradoxically, cardiovascular risk stratification.

Interactions

rs30021 is listed as a co-variant alongside rs11967262 — a VEGFA upstream regulatory variant strongly associated with varicose veins through the 6p21.1 locus. The co-listing reflects their co-occurrence in varicose vein genetic research rather than physical LD (they are on different chromosomes: rs30021 on chr5, rs11967262 on chr6). Their functional connection is through the shared biological theme of vascular wall integrity and endothelial growth factor signaling.

Another SNX24 variant, rs28891, was specifically associated with coronary artery aneurysm risk in Kawasaki disease. Individuals carrying rs30021-G who also have other variants affecting VWF production (VWF gene variants) or platelet function may have compound effects on hemostasis worth discussing with a hematologist.

Genotype Interpretations

What each possible genotype means for this variant.

AA Common Variant Normal

Common genotype — full SNX24 function expected

You carry two copies of the A allele at rs30021, the common genotype shared by approximately 59% of people globally. This is the population-majority genotype at this locus. In the absence of evidence that A allele homozygosity impairs SNX24 function, this genotype is not associated with altered vascular inflammation signaling or platelet alpha-granule biology through this variant. Other genetic and lifestyle factors govern your cardiovascular and hemostatic profile.

AG G Allele Carrier Intermediate

One G allele — possible partial reduction in SNX24 activity

The evidence for rs30021 as a functional variant is indirect. The best available data show that SNX24 protein is required for VWF and P-selectin loading into platelet alpha-granules, and that endothelial cells with reduced SNX24 expression produce less IL-1β, IL-6, and IL-8. A related SNX24 variant (rs28891) associates with coronary artery aneurysm risk in Kawasaki disease, establishing that SNX24 genetic variation matters in cardiovascular outcomes.

With one G allele, any effect on SNX24 expression would be expected to be partial — heterozygotes generally show intermediate expression levels when a variant affects regulatory elements. The practical significance is uncertain enough that monitoring rather than active supplementation is the evidence-grounded response.

GG G Homozygous High Risk

Two G alleles — minor homozygous genotype with uncertain SNX24 expression impact

The GG genotype is the most uncommon at this locus (~6% globally). Because rs30021 is a deeply intronic variant (c.249+4040G>A, positioned 4,040 bp downstream of the nearest exon boundary), its mechanism of action would be regulatory rather than protein-altering. Such variants can influence RNA splicing efficiency, intronic regulatory element binding, or chromatin looping — but none of these effects have been measured for rs30021 specifically.

What is established is the importance of SNX24 itself: CRISPR knockout megakaryocytes show absent alpha-granule biogenesis and lost VWF trafficking, while endothelial SNX24 silencing reduces the pro-inflammatory cytokine response. A coding SNX24 variant (rs28891) in the same gene associates with reduced coronary artery aneurysm severity in pediatric Kawasaki disease, possibly through reduced endothelial inflammatory signaling.

For GG carriers, the combination of possible reduced platelet alpha-granule VWF release and altered endothelial cytokine signaling warrants proactive hemostatic profiling and monitoring of inflammatory markers, particularly if there is a personal or family history of bleeding tendency, varicose veins, or coronary artery disease.